Method for preparing composite preparation for treating lung cancer

Abstract

The invention provides a preparation method of a compound preparation for treating lung cancer, and the method comprises the following steps: raw material plasma is respectively taken from a blood bank according to the different blood types, low-density lipoprotein is extracted from the plasma by centrifugation and density adjustment treatment, a targeted-drug carrier is prepared by extracting and purifying the low-density lipoprotein, then the targeted-drug carrier is compounded with an aclacinomycin targeted-drug for treating cancer, and the low-density lipoprotein-aclacinomycin drug after the compound is injected into a patient with the same blood type of the raw material plasma of the drug to achieve the purpose of treating the lung cancer. The clinical practices prove that the low-density lipoprotein-aclacinomycin compound injection preparation can obtain the satisfying efficacy on the clinical treatment of the lung cancer without obvious chemotherapy toxicity or side effects; in 352 cases of the patients with the lung cancer, the effective rate achieves 100 percent, and the 3-year survival rate is more than 96 percent, thereby having great promotion and use values.

Description

technical field [0001] The invention relates to a chemotherapy preparation for treating lung cancer, in particular to a preparation method of a compound preparation for treating lung cancer and a preparation method thereof. Background technique [0002] With the aggravation of environmental pollution, the incidence and mortality of lung cancer are increasing year by year, seriously endangering the health of the people. In the treatment plan of lung cancer, chemotherapy is still the main means in its comprehensive treatment measures. At present, the common deficiency of the chemotherapeutic drugs used in the chemotherapy of various tumors is that the anti-tumor chemotherapeutic drugs lack selectivity. While killing cancer cells, they also damage healthy cells, reduce the immune function of the human body, and cause many toxic effects. Side effects affect the clinical application of chemotherapy drugs. In order to improve the efficacy of anti-tumor drugs and reduce the damage...

AI Technical Summary

Problems solved by technology

At present, the common deficiency of the chemotherapeutic drugs used in the chemotherapy of various tumors is that the anti-tumor chemotherapeutic drugs lack selectivity. While killing cancer cells, they also damage healthy cells, reduce the immune function of the human body, and cause many toxic effects. Side effects affect the clinical application of chemotherapy drugs. In order to improve the efficacy of anti-tumor drugs and reduce the damage and toxicity to normal cells, the medical community has tried many times to use antibodies, liposomes, hormones and other macromolecules as tumor chemotherapy drugs. Carriers, in order to increase the targeting of drugs, that is, "targeted therapy"

However, a major problem in the actual clinical application process is that the reticuloendothelial system of the liver and spleen removes these complexes in the blood as foreign harmful substances and quickly removes them from the blood stream, thereby reducing the impact of the drug-macromolecular complex on the bloodstream. The time of action of tumor cells affects the therapeutic effect of drugs